FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
Season 8, Episode 3, Dec 05, 2022, 07:00 PM
Dr Matulonis discusses the FDA approval of mirvetuximab soravtansine-gynx in folate receptor alpha–positive, platinum-resistant ovarian cancer, key efficacy and safety data from the SORAYA trial, and how further research can continue the momentum behind finding effective ovarian cancer treatments.